Clinical Trial Update: mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line [Phase 2]

View source ↗

Summary

Phase 2 trial comparing mFOLFOX vs. mFOLFIRI in advanced or recurrent biliary tract cancer refractory to first-line therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• mFOLFIRI
• mFOLFOX

Snippet

Sponsor: Seoul National University Bundang Hospital | Conditions: Biliary Cancer Metastatic | Phase 2 | Status: COMPLETED